Oral Cancer

Nagpur-based biotech startup ErlySign has claimed to have developed India’s first saliva-based test for detecting oral precancerous conditions, delivering results in 15 minutes. This technology utilises biomarkers (MMP2 and MMP9), offering a non-invasive solution for early cancer detection. The test, leveraging biomarkers, claims 98.04 per cent sensitivity and 100 per cent specificity, indicating high accuracy. ErlySign recently secured Rs 16 crore in pre-Series A funding, led by investor Ashish Kacholia. These funds will enable the startup to finalise clinical trials, secure approvals from the Central Drugs Standard Control Organisation (CDSCO), and bring its product to market. The company anticipates completing trials and obtaining regulatory clearance by Q2 2026.